EJCTS Click here to go to Siemens website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Branscheid, D.
Right arrow Articles by Vogt-Moykopf, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Branscheid, D.
Right arrow Articles by Vogt-Moykopf, I.

European Journal of Cardio-Thoracic Surgery, Vol 6, 590-596, Copyright © 1992 by European Association for Cardio-thoracic Surgery


ARTICLES

Does ND-YAG laser extend the indications for resection of pulmonary metastases?

D Branscheid, S Krysa, G Wollkopf, H Bulzebruck, G Probst, M Horn, J Schirren and I Vogt-Moykopf
Chirurgische Abteilung, Thoraxklinik Heidelberg-Rohrbach, FRG.

Surgery forms part of a combined oncological concept in the management of pulmonary metastases. The following questions are relevant for its role: Does survival depend on the type of primary tumor? Are there any prognostic factors? What are the limits on radical resection? We analyzed retrospectively 657 patients who had undergone 759 resections of pulmonary metastases between 1973 and 1990. After conducting in vitro and in vivo experiments with the non-contact neodymium aluminum garnet (Nd-YAG) laser with a generating and delivery power of 10-120 W at the site of operation for 0.1-9.9 s, we have treated 65 patients by laser resection and/or vaporization since January 1990. Our preferred surgical approach was median or transverse thoracotomy. The 5-year survival of all resected patients was 30%, ranging from 21% (soft tissue sarcoma) to 60% (testicular carcinoma). Statistically significant differences in prognosis were seen related to the type of primary tumor, the disease-free interval, the caval or portal type of metastatic spread, the number of metastases and the potential degree of radical resection. The potential degree of conventional radical resections (wedge, anatomical sub-/segmental) was negatively influenced by the number of metastases (n > 9: 79% "radical" surgery = 38% 5-year survival). Laser treatment allowed parenchyma-preserving resection in cases of metastases of more than 0.5 cm in diameter, and vaporization in smaller ones. Resection with the intention of achieving complete remission was possible in up to 72 unilateral metastases. The complication rate was comparable to conventional resections.


This article has been cited by other articles:


Home page
MMCTSHome page
A. Rolle and A. Pereszlenyi
Laser resection of lung metastasis
MMCTS, June 28, 2005; 2005(0628): 570.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
U. Eichfeld, A. Tannapfel, M. Steinert, and T. Friedrich
Evaluation of ultracision in lung metastatic surgery
Ann. Thorac. Surg., October 1, 2000; 70(4): 1181 - 1184.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1992 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.